<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22460270</article-id><article-id pub-id-type="pmc">3341944</article-id><article-id pub-id-type="pii">bjc2012100</article-id><article-id pub-id-type="doi">10.1038/bjc.2012.100</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Randomised phase II trial of docetaxel and sunitinib in patients with metastatic
gastric cancer who were previously treated with fluoropyrimidine and platinum</article-title><alt-title alt-title-type="running">Second-line docetaxel and sunitinib in AGC</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yi</surname><given-names>J H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><xref ref-type="corresp" rid="caf1">*</xref><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>S H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>J O</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yim</surname><given-names>D-S</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Y S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lim</surname><given-names>H Y</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>W K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1"><label>1</label><institution>Division of Hematology-Oncology, Department
of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine</institution>,
50 Irwon-dong, Gangnam-Gu, Seoul
135-710, <country>Korea</country></aff><aff id="aff2"><label>2</label><institution>Department of Medicine, Division of Medical
Oncology, Yonsei Cancer Center, Yonsei University College of Medicine</institution>,
Seoul, <country>Korea</country></aff><aff id="aff3"><label>3</label><institution>Department of Pharmacology, The Catholic
University of Korea</institution>, Seoul St. Mary's Hospital, 222 Banpodaero,
Seocho-gu, Seoul, <country>Korea</country></aff><aff id="aff4"><label>4</label><institution>Department of Clinical Pharmacology and
Therapeutics</institution>, Seoul St. Mary's Hospital, 222 Banpodaero,
Seocho-gu, Seoul, <country>Korea</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>jyunlee@skku.edu</email></corresp></author-notes><pub-date pub-type="ppub"><day>24</day><month>04</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>29</day><month>03</month><year>2012</year></pub-date><volume>106</volume><issue>9</issue><fpage>1469</fpage><lpage>1474</lpage><history><date date-type="received"><day>12</day><month>12</month><year>2011</year></date><date date-type="rev-recd"><day>24</day><month>02</month><year>2012</year></date><date date-type="accepted"><day>28</day><month>02</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2012 Cancer Research UK</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Cancer Research UK</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><license-p>From twelve months after its original publication, this work is licensed under
the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a
copy of this license, visit
http://creativecommons.org/licenses/by-nc-sa/3.0/</license-p></license></permissions><abstract><sec><title>Background:</title><p>Docetaxel is widely used as a chemotherapeutic agent for gastric cancer treatment. A
combined regimen with sunitinib demonstrated a synergistic antitumour effect in a
preclinical model. The aim of this study was to evaluate the efficacy and safety of this
combination in patients with unresectable or metastatic advanced gastric cancer
following failure of treatment with a fluoropyrimidine and platinum combination.</p></sec><sec><title>Methods:</title><p>This open-label, phase II, randomised trial enrolled patients with unresectable or
metastatic gastric cancer. Patients were assigned to either a docetaxel monotherapy arm
(D only arm: 60&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, every 3 weeks) or a combination
arm (DS arm: docetaxel&#x0002b;sunitinib 37.5&#x02009;mg every day). The primary end point
of the study was time to progression and the secondary end points were overall response
rate, disease control rate, overall survival, and toxicity profile. A pharmacokinetic
study was also performed.</p></sec><sec><title>Results:</title><p>A total of 107 patients were entered into the study. The TTP was not significantly
prolonged in the DS arm when compared with the D only arm (DS <italic>vs</italic> D only arm:
3.9 months (95&#x00025; confidence interval (CI) 2.9&#x02013;4.9) <italic>vs</italic> 2.6 months
(95&#x00025; CI 1.8&#x02013;3.5) (<italic>P</italic>=0.206). The hazard ratio for TTP was
0.77 (95&#x00025; CI 0.52&#x02013;1.16). However, the objective response rate was
significantly higher in the DS arm (41.1&#x00025; <italic>vs</italic> 14.3&#x00025;,
<italic>P</italic>=0.002). Patients in the DS arm experienced stomatitis, diarrhoea, and
hand&#x02013;foot syndrome more frequently.</p></sec><sec><title>Conclusion:</title><p>The addition of sunitinib to docetaxel did not significantly prolong TTP, although it
significantly increased response.</p></sec></abstract><kwd-group><kwd>gastric cancer</kwd><kwd>second-line chemotherapy</kwd><kwd>docetaxel</kwd><kwd>sunitinib</kwd></kwd-group></article-meta></front><body><p>Gastric cancer is the fourth most common cancer worldwide, with nearly one million new
cases diagnosed every year (<xref ref-type="bibr" rid="bib14">Jemal <italic>et al</italic>, 2011</xref>). It
is also one of the leading causes of cancer-related mortality in Asia (<xref ref-type="bibr" rid="bib15">Jung <italic>et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="bib29">Tanaka <italic>et al</italic>,
2011</xref>). For patients with recurrent or metastatic disease, chemotherapy can
improve survival and can also possibly provide significant palliation of symptoms (<xref ref-type="bibr" rid="bib26">Pyrhonen <italic>et al</italic>, 1995</xref>; <xref ref-type="bibr" rid="bib12">Glimelius <italic>et
al</italic>, 1997</xref>). In terms of first-line regimens, a combination of
fluoropyrimidine and platinum is regarded as a standard option as this combination has shown
superior clinical outcomes in phase III trials when compared with fluoropyrimidine
monotherapy and other combinations (<xref ref-type="bibr" rid="bib33">Wagner <italic>et al</italic>,
2006</xref>). However, less than half of the patients achieve an objective response and
the duration, even in these responders, is as short as a few months (<xref ref-type="bibr" rid="bib30">Van Cutsem <italic>et al</italic>, 2002</xref>).</p><p>Recently, we have conducted a randomised phase III trial to compare best supportive care
<italic>vs</italic> best supportive care plus chemotherapy (irinotecan or docetaxel) following the
failure of fluropyrimidine/platinum-based chemotherapy for the treatment of gastric
cancer. In this phase III trial, 193 gastric cancer patients were randomly assigned to
second-line chemotherapy (<italic>n</italic>=128) or best supportive care
(<italic>n</italic>=65). A significant prolongation in survival was observed for the
second-line chemotherapy arm when compared with best supportive care (hazard ratio, 0.63;
95&#x00025; CI, 0.47&#x02013;0.86; <italic>P</italic>=0.004) (<xref ref-type="bibr" rid="bib24">Park <italic>et
al</italic>, 2011</xref>). Thus, second-line chemotherapy should be considered in
selected patients with gastric cancer.</p><p>Docetaxel is one of the most widely used chemotherapeutic agents for the second-line
treatment of gastric cancer. Docetaxel exerts its antitumour activity by stabilising
microtubules. It also inhibits the anti-apoptotic gene <italic>Bcl2</italic> and promotes the
expression of p27, a cell-cycle inhibitor, as well as other pro-angiogenic factors, such as
vascular endothelial growth factor (VEGF) (<xref ref-type="bibr" rid="bib22">Nishiyama and Wada,
2009</xref>). As a monotherapy, this agent has shown an overall response rate of around
15&#x00025; and time to progression (TTP) of 2.5&#x02013;3 months (<xref ref-type="bibr" rid="bib3">Bang
<italic>et al</italic>, 2002</xref>; <xref ref-type="bibr" rid="bib11">Giuliani <italic>et al</italic>,
2003</xref>; <xref ref-type="bibr" rid="bib17">Lee <italic>et al</italic>, 2008</xref>). Combination of
docetaxel with other agents, such as platinum as a treatment for gastric cancer, has failed
to demonstrate any significant improvement in efficacy in most studies, when compared with
docetaxel alone (<xref ref-type="bibr" rid="bib25">Park <italic>et al</italic>, 2004</xref>; <xref ref-type="bibr" rid="bib21">Nguyen <italic>et al</italic>, 2006</xref>; <xref ref-type="bibr" rid="bib5">Barone <italic>et
al</italic>, 2007</xref>; <xref ref-type="bibr" rid="bib34">Zhong <italic>et al</italic>, 2008</xref>;
<xref ref-type="bibr" rid="bib16">Kim <italic>et al</italic>, 2011</xref>). Although one study has shown
that the addition of docetaxel was associated with improved clinical outcomes (<xref ref-type="bibr" rid="bib31">Van Cutsem <italic>et al</italic>, 2006</xref>), docetaxel is not widely
recommended as a standard treatment option because of its high rate of toxicity, including
neutropenia and neurotoxicity, and also the need for subsequent discontinuation of the
treatment (<xref ref-type="bibr" rid="bib13">Ilson, 2007</xref>).</p><p>Sunitinib is an oral inhibitor of multiple receptor tyrosine kinases that are involved in
tumour proliferation and angiogenesis, specifically platelet-derived growth factor receptor,
VEGF receptor, KIT, Flt-3, and RET (<xref ref-type="bibr" rid="bib1">Abrams <italic>et al</italic>,
2003a</xref>; <xref ref-type="bibr" rid="bib18">Mendel <italic>et al</italic>, 2003</xref>; <xref ref-type="bibr" rid="bib23">O'Farrell <italic>et al</italic>, 2003</xref>). This agent has shown efficacy
against many solid cancers, including metastatic clear cell renal cell carcinoma (<xref ref-type="bibr" rid="bib20">Motzer <italic>et al</italic>, 2009</xref>), imatinib-refractory gastrointestinal
stromal tumour (<xref ref-type="bibr" rid="bib9">Demetri <italic>et al</italic>, 2006</xref>), and pancreatic
neuroendocrine tumour (<xref ref-type="bibr" rid="bib27">Raymond <italic>et al</italic>, 2011</xref>). In
preclinical studies, docetaxel and sunitinib demonstrated additive antitumour activity in
mouse xenograft models of non-small-cell lung cancer and breast cancer (<xref ref-type="bibr" rid="bib2">Abrams <italic>et al</italic>, 2003b</xref>; <xref ref-type="bibr" rid="bib7">Christensen JG</xref>).
Recently, in a multicentre, phase II trial, single-agent sunitinib given in a second-line
setting demonstrated an overall response rate of 2.6&#x00025; with 32.1&#x00025; of stable
disease lasting more than 6 weeks and manageable toxicity in patients with advanced gastric
cancer (AGC) (<xref ref-type="bibr" rid="bib4">Bang <italic>et al</italic>, 2010</xref>). In the present
study, we conducted a randomised, phase II trial of docetaxel singly or in combination with
sunitinib in patients who had experienced failure of fluoropyrimidine and platinum therapy.
This study is registered at clinicaltrials.gov as &#x00023;NCT01238055.</p><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Study design</title><p>This was an open-label, phase II, two arm, randomised, single centre study conducted at
Samsung Medical Center, Seoul, Korea. The protocol was approved by the institutional
review board at Samsung Medical Center and the trial was conducted in accordance with
the Declaration of Helsinki. All patients were required to give written informed consent
before enrolment. Pfizer (Seoul, Korea) provided sunitinib <italic>gratis</italic>, but was not
involved in the accrual or analysis of the data or in the preparation of the
manuscript.</p></sec><sec><title>Patients</title><p>Patients aged &#x02a7e;18 years with unresectable or metastatic adenocarcinoma of the
stomach or gastroesophageal junction, whose cancer had progressed after a first-line
fluoropyrimidine and platinum combination regimen, were eligible to enter the study.
Other eligibility criteria were as follows: measurable or evaluable disease according to
the Response Evaluation Criteria in Solid Tumours (RECIST) 1.1; performance status
0&#x02013;2 by Eastern Cooperative Oncology Group scale; adequate organ function including
bone marrow (absolute neutrophil count
&#x02a7e;1500&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup>, platelet
&#x02a7e;100&#x02009;000&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup>), liver
(AST/ALT&#x02a7d;2.5 &#x000d7; ULN, 5.0 &#x000d7; ULN if liver involvement, total serum
bilirubin &#x02a7d;2.0&#x02009;mg&#x02009;dl<sup>&#x02212;1</sup>) and kidney (serum creatinine
&#x02a7d;1.5 &#x000d7; ULN); life expectancy of more than 3 months; and written informed
consent. Patients with severe co-morbid illness and/or active infections, grade 3 or
higher haemorrhage according to CTCAE v3.0 (US National Cancer Institute) within prior 4
weeks, pregnant or lactating women, or active CNS metastases not controllable with
radiotherapy or corticosteroids were excluded from the study.</p></sec><sec><title>Treatment</title><p>Patients were randomised in 1&#x02009;:&#x02009;1 ratio either to a docetaxel plus
sunitinib (DS arm) arm or to a docetaxel single arm (D only arm) using a random permuted
block design. Random assignment was stratified by ECOG performance status (0, 1
<italic>vs</italic> 2). Docetaxel was administered at the dose of
60&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> on day 1 of each 3-week cycle and sunitinib
was administered orally at the starting dose of 37.5&#x02009;mg daily, on a continuous
daily dosing schedule. Tumour evaluation was performed every two cycles and response to
chemotherapy was assessed in accordance with the RECIST criteria v1.1. Clinical
laboratory evaluations (biochemistry, haematology, and urinalysis) were carried out on
day 1 of every cycle. Toxicity assessment adhered to CTCAE v3.0. Treatment was
discontinued in case of tumour progression, unacceptable toxicity, or consent
withdrawal. No crossover to the DS arm was allowed for patients in the D only arm after
progression.</p><p>For patients receiving docetaxel administration, if grade 4 neutropenia, febrile
neutropenia, skin/nail changes, or grade 2 peripheral neuropathy developed, dose was
reduced to 45&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>. If a patient continued to
experience these toxicities (other than neuropathy) at
45&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, treatment was discontinued. In terms of
peripheral neuropathy, treatment was discontinued if grade 3 or 4 toxicity was
developed. For patients receiving sunitinib administration, if grade 3 toxicity
developed, sunitinib was withheld until the toxicity was resolved to &#x0003c;grade 2, then
treatment was reduced to 25&#x02009;mg. If a second occurrence of &#x0003e;grade 1 toxicity
occurred, sunitinib was further reduced to 12.5&#x02009;mg. At a third occurrence of
&#x0003e;grade 1 toxicity, sunitinib was discontinued.</p></sec><sec><title>Pharmacokinetic analysis</title><p>Average steady-state plasma concentrations (<italic>C</italic><sub>ss,av</sub>) for sunitinib
and its active metabolite SU12662 were measured on the last day of cycles 2, 4, and 6,
before drug administration of the next cycle. All the samples were centrifuged at
2092&#x02009;<bold>g</bold> for 10&#x02009;min immediately after collection, and stored frozen
at &#x02212;70&#x02009;&#x000b0;C until assayed. Plasma concentrations of sunitinib and SU12662
were determined by high performance liquid chromatography coupled with tandem mass
spectrometry. The lower limit of quantification was 0.25&#x02009;ngml<sup>&#x02212;1</sup>
for sunitinib and SU12662.</p><p>Data analysis was performed on the intent-to-treat population using the last
observation carried forward method for missing data. Dose-normalised
<italic>C</italic><sub>ss,av</sub> of sunitinib and SU12662 at each cycle was analysed by
repeated-measures ANOVA (SAS, version 9.1; SAS Institute Inc., Cary, NC, USA).</p></sec><sec><title>Statistics</title><p>The primary end point of the current study was TTP, which was defined as the interval
between the date of first study treatment and the date of documented disease
progression. The secondary end points were objective response rate (ORR), disease
control rate (DCR), and overall survival (OS), which was calculated from the date of
first study treatment to the date of death and toxicity profile. TTP and OS were
calculated by the Kaplan&#x02013;Meier product&#x02013;limit method.</p><p>For sample size calculation, we initially assumed 12 months of accrual period and 6
months of follow-up period. The current study was designed with two-sided,
<italic>&#x003b1;</italic>=0.05, 90&#x00025; power to detect a null median TTP of 2 months
and experimental median TTP of 4 months (<italic>N</italic>=108). Assuming a 10&#x00025;
dropout rate, total target accrual number was 116 (108&#x0002b;10&#x00025;). The sample size
was recalculated on February 2011 owing to a longer patient accrual period (&#x0003e;24
months) than originally planned (12 months). The revised sample size calculation was
designed with two-sided, <italic>&#x003b1;</italic>=0.05, 90&#x00025; power to detect a null
median TTP of 2 months and experimental median TTP of 4 months (<italic>N</italic>=108)
after a 36-month accrual period and 18-month follow-up (<italic>N</italic>=92). We
amended the protocol to accrue 102 patients. The laboratory data and prognostic factors
obtained from demographic data on the baseline were evaluated by Pearson's
Chi-square test for patient homogeneity on the baseline between the two arms and the
associations among the prognostic factors. The efficacy and toxicity of the two arms
were evaluated by comparing response rate, DCR, and incidence of toxicity using
Pearson's chi-square tests, while TTP and OS were compared by log-rank tests. For
pharmacokinetic study, the protocol was amended (at the time of 80 patient accrual) to
enrol patients for pharmacokinetic blood sampling. Those patients who had consented for
pharmacokinetic sampling, which was not mandatory, were enrolled.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Patient characteristics</title><p>Between December 2008 and February 2011, 107 patients were entered into the study. As 2
patients withdrew their consent before treatment, clinical outcomes and toxicities were
evaluated in 105 patients. The median age of the patients was 53 years (20&#x02013;72) and
male&#x02009;:&#x02009;female ratio was 73 (69.5&#x00025;)&#x02009;:&#x02009;32
(30.5&#x00025;). The ECOG performance scale indicated a grade of 0&#x02013;1 for 96
(91.4&#x00025;) patients. After randomisation, 56 patients (53.3&#x00025;) were allocated
to the DS arm and 49 patients (46.7&#x00025;) to the docetaxel arm (D only arm).
Demographics of the two arms, including median age, sex ratio, ECOG performance scale,
laboratory findings (except serum alkaline phosphatase level), and sites of metastatic
lesions, were not significantly different. These details are provided in <xref rid="tbl1" ref-type="table">Table 1</xref>.</p></sec><sec><title>Pharmacokinetic analysis</title><p>A total of 66 plasma concentrations (33 for sunitinib, 33 for SU12662) from 13 patients
were analysed. No differences were noted in the dose-normalised
<italic>C</italic><sub>ss,av</sub> of sunitinib and SU12662 over the cycle using
repeated-measures ANOVA (<xref rid="tbl2" ref-type="table">Table 2</xref> and <xref ref-type="fig" rid="fig1">Figure 1</xref>).</p></sec><sec><title>Treatment response and survival</title><p>A total of 423 cycles were administered, with a median of three cycles given per
patient (range 1&#x02013;18). No significant difference was noted between the DS and D
only arms in terms of the median number of treatment cycles (<italic>P</italic>=0.283).
At the time of analysis, 97 cases (92.3&#x00025;) of progression had occurred, including
52 cases (92.9&#x00025;) in the DS arm and 45 cases (91.8&#x00025;) in the D only arm. The
TTP was not significantly prolonged in the DS arm when compared with the D only arm (DS
<italic>vs</italic> D only arm: 3.9 months (95&#x00025; confidence interval (CI) 2.9&#x02013;4.9)
<italic>vs</italic> 2.6 months (95&#x00025; CI 1.8&#x02013;3.5), <italic>P</italic>=0.206)
(<xref ref-type="fig" rid="fig2">Figure 2</xref>). The hazard ratio for TTP was 0.77 (95&#x00025;
CI 0.52&#x02013;1.16). The response rate was significantly higher for the DS arm than for
the D only arm (DS <italic>vs</italic> D only arm: 41.1&#x00025; (95&#x00025; CI 28.1&#x02013;55.0)
<italic>vs</italic> 14.3&#x00025; (95&#x00025; CI 6.0&#x02013;27.2), <italic>P</italic>=0.002)
(<xref rid="tbl3" ref-type="table">Table 3</xref>). Notably, one patient with multiple liver
metastases achieved complete remission after 4 cycles of docetaxel and sunitinib. The
patient is still maintaining complete remission after completion of 4 cycles of
docetaxel and sunitinib (that is, for more than 2 years) at the time of this writing
(<xref ref-type="fig" rid="fig3">Figure 3</xref>). The DS arm had 1 CR, 29 PRs, 37 SDs, and 38
PDs, by RECIST 1.1. All treatment responses were centrally reviewed while blinded to the
treatment arm. A similar tendency was observed for the DCR, which was 75.0&#x00025;
(42/56, 95&#x00025; CI 61.6&#x02013;85.6) in the DS arm and 51.0&#x00025; (25/49,
95&#x00025; CI 36.3&#x02013;65.6) in the D only arm (<italic>P</italic>=0.011, <xref rid="tbl3" ref-type="table">Table 3</xref>).</p><p>The DS regimen did not significantly improve survival when compared with the D only
regimen (DS <italic>vs</italic> D only arm: 8.0 (95&#x00025; CI 5.4&#x02013;10.6) <italic>vs</italic> 6.6
(95&#x00025; CI 3.6&#x02013;9.7), <italic>P</italic>=0.802) (<xref ref-type="fig" rid="fig4">Figure
4</xref>). The hazard ratio for OS was 0.94 (95&#x00025; CI 0.60&#x02013;1.49).</p></sec><sec><title>Adverse events</title><p>Among the 105 patients whose toxicity profile was assessed, 64 patients (61.0&#x00025;)
experienced grade at least one grade 3&#x02013;4 adverse event (AE). The most common grade
3&#x02013;4 AE was neutropenia, which occurred in 18 patients (32.1&#x00025;) in the DS arm
and 10 patients (20.4&#x00025;) in the D only arm. Overall, the incidence of grade
3&#x02013;4 AEs was not significantly different between the two arms (46.4&#x00025;
(26/56) in the DS arm, 30.6&#x00025; (15/49) in the D only arm,
<italic>P</italic>=0.112). In addition, no statistical difference was observed between
the two groups in terms of haematological toxicity (including anaemia, leukopenia,
neutropenia, thrombocytopenia, and febrile neutropenia), nausea, vomiting, neuropathy,
and myalgia. However, patients who received docetaxel and sunitinib had a greater chance
of experiencing stomatitis, diarrhoea, and hand&#x02013;foot syndrome (HFS) than did those
who received docetaxel only. These details are described in <xref rid="tbl4" ref-type="table">Table
4</xref>.</p><p>The occurrence of these AEs led to at least one cycle of dose reduction in 46
(43.8&#x00025;) patients and treatment delay in 57 (54.3&#x00025;) patients. The DS arm
showed 39 and 50 cases of dose reduction and treatment delay, respectively, out of 230
cycles of treatment. The D only arm showed 23 and 44 cases of dose reduction and
treatment delay, respectively, out of 193 cycles. Occurrences of dose reduction
(29/56, 51.8&#x00025; in arm A, 17/49, 34.7&#x00025; in arm B,
<italic>P</italic>=0.078) and treatment delay (32/56, 57.1&#x00025; in arm A,
25/49, 51&#x00025; in arm B, <italic>P</italic>=0.530) were not significantly
different between the two groups. The dose intensity was 65&#x00025; of the planned dose
for docetaxel and 60&#x00025; of the planned dose for sunitinib.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In this phase II randomised study, we analysed the efficacy and toxicity of 3-weekly
administration of docetaxel 60&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> combined with daily
administration of sunitinib 37.5&#x02009;mg in patients with AGC who had failed to respond
to first-line fluoropyrimidine and platinum. The current study showed the following
findings: (1) combination of docetaxel and sunitinib demonstrated a median TTP of 3.9
months (95&#x00025; CI 2.9&#x02013;4.9), while docetaxel monotherapy demonstrated a median
TTP of 2.6 months (95&#x00025; CI 1.8&#x02013;3.5) (<italic>P</italic>=0.206). Importantly,
patients who had received the combined treatment showed significantly higher ORR (DS
<italic>vs</italic> D only arm: 41.1&#x00025; <italic>vs</italic> 14.3&#x00025;, <italic>P</italic>=0.002).
However, patients in the DS arm experienced stomatitis, diarrhoea, and HFS more frequently
than did patients in the D only arm.</p><p>In the current study, 56 patients received docetaxel combined with sunitinib.
Importantly, one patient who had multiple liver metastases from gastric cancer, and who
had failed to respond to previous TS-1/cisplatin chemotherapy, achieved complete
remission after docetaxel/sunitinib and has maintained remission for &#x0003e;2 years
(<xref ref-type="fig" rid="fig3">Figure 3</xref>). The high response rate with the docetaxel and
sunitinib combination in gastric cancer suggests that this regimen might be feasible in a
neoadjuvant setting where response rate is important. Although the DS regimen did not
prolong TTP in all GC patients, the regimen substantially increased response rate and thus
may be important as a preoperative regimen in gastric cancer patients with limited
metastases. In addition, the docetaxel and sunitinib combination may be tested in the
first-line setting for gastric cancer. Based on our phase III trial which compared
docetaxel, irinotecan and supportive care in salvage setting for gastric cancer,
irinotecan monotherapy seemed better than docetaxel alone (<xref ref-type="bibr" rid="bib24">Park
<italic>et al</italic>, 2011</xref>). However, at the time of the study design, the phase
III trial was ongoing and there was lack of preclinical data for irinotecan and sunitinib
combination. There are few phase I dose-finding studies for the combination of sunitinib
and docetaxel (<xref ref-type="bibr" rid="bib28">Robert <italic>et al</italic>, 2010</xref>; <xref ref-type="bibr" rid="bib8">de Jonge <italic>et al</italic>, 2011</xref>). The recommended dose for the
combination was docetaxel 75&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> q 3 weeks and sunitinib
37.5&#x02009;mg daily. Initially, we had planned to administer the above regimen. However,
the first two patients had grade 4 neutropenia with febrile episode. After internal
discussion with the internal safety monitoring board, we had decided to lower the dose to
docetaxel 60&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> and sunitinib 37.5&#x02009;mg daily
every 3 weeks.</p><p>The PK results of sunitinib and SU12662 obtained at steady-state were similar to those
from single-agent trials in patients with advanced solid malignancies (<xref ref-type="bibr" rid="bib6">Britten <italic>et al</italic>, 2008</xref>). As mentioned earlier, no difference was
observed for the dose-normalised <italic>C</italic><sub>ss,av</sub> of sunitinib and SU12662 over
the cycle. Therefore, the conclusion may be made that autoinduction or autoinhibition of
sunitinib or SU12662 metabolism has not been observed with prolonged dosing.</p><p>Identification of predictive biomarkers that could identify the subset of gastric cancer
patients who might dramatically respond to docetaxel and sunitinib will be clinically
important. Although our study failed to demonstrate improved TTP in the docetaxel and
sunitinib combination arm, it did indicate that some gastric cancer patients may respond
dramatically to a combined docetaxel and sunitinib treatment. Identification of key
biomarkers that might predict treatment response to sunitinib will aid clinicians in
designing future enriched clinical trials on sunitinib as a treatment for metastatic
gastric cancer. Currently, no specific biomarker has been identified that can predict
treatment response to sunitinib.</p><p>The German Arbeitsgemeinschaft Internistische Onkologie (AIO) study investigated the
associations between serum VEGF-C concentrations and treatment outcome in a phase II
sunitinib monotherapy trial for gastric cancer (<xref ref-type="bibr" rid="bib19">Moehler <italic>et
al</italic>, 2011</xref>). However, owing to limited tissue availability, the biomarker
study in the AIO study was not conclusive. Recent pharmacogenetic analysis has revealed
that patients harbouring certain single-nucleotide polymorphisms (SNPs) are predisposed to
experience more frequent toxicities or lower response (<xref ref-type="bibr" rid="bib32">van Erp <italic>et
al</italic>, 2009</xref>; <xref ref-type="bibr" rid="bib10">Garcia-Donas <italic>et al</italic>,
2011</xref>) when treated with sunitinib. We have collected serial blood samples as
well as paraffin-embedded tissues for further correlative analyses and soon will report
the predictive and prognostic role of those SNPs in sunitinib treatment.</p><p>Grade 3&#x02013;4 neutropenia, which is a serious toxicity of the docetaxel and sunitinib
combination, occurred in 18 patients (32.1&#x00025;) in the DS arm and 10 patients in the D
arm (<italic>P</italic>=0.169). Overall, the incidences of other haematological toxicities
including anaemia, leukopenia, or thrombocytopenia were not significantly different
between the two groups. The incidence of febrile neutropenia was not significantly
different in the two arms (<italic>P</italic>=0.196) and no subsequent mortality was
observed. Although this could be the result of the small number of the recruited patients,
we authors do not consider this AE to be a major problem for the docetaxel and sunitinib
combination treatment.</p><p>However, in the DS arm, the incidences of any grade of stomatitis, diarrhoea, and HFS
were more frequent than in the D arm, with statistical significance (any grade stomatitis:
51.8&#x00025; <italic>vs</italic> 14.3&#x00025; (<italic>P</italic>&#x0003c;0.001); any grade diarrhea:
35.7&#x00025; <italic>vs</italic> 14.2&#x00025; (<italic>P</italic>=0.033); any grade HFS:
53.6&#x00025; <italic>vs</italic> 20.4&#x00025; (<italic>P</italic>=0.002)). Because of these AEs, a
substantial number of patients needed treatment modifications. Patients who had received
the DS treatment showed a tendency to experience more frequent dose reductions, but the
difference was not statistically significant (29/56, 51.8&#x00025; in arm DS,
17/49, 34.7&#x00025; in arm D, <italic>P</italic>=0.078). Therefore, we might conclude
that future clinical trials will combine sunitinib and conventional chemotherapeutic
agents safely, by providing appropriate management of the AEs.</p><p>In conclusion, although the primary end point has not been met in this randomised phase
II trial, the study has demonstrated that the addition of sunitinib can substantially
improve response rate in metastatic gastric cancer in a second-line setting. Compared with
docetaxel monotherapy, the addition of sunitinib was not associated with additional
toxicity except stomatitis, diarrhoea, and HFS, and was not associated with more frequent
treatment modification. The observation of some long-term responders indicates that the
clinical development of sunitinib should still be pursued for treatment of gastric cancer.
Especially with the advent of the personalised medicine, we should focus on exploring
biomarkers that could identify those few gastric cancer patients who would dramatically
respond to sunitinib.</p></sec></body><back><ack><p>This study was supported by SMC CRDP grant no. CRS109452. Pfizer provided sunitinib
<italic>gratis</italic>, but the company was not involved in the accrual or analysis of the data,
or in the preparation of the manuscript.</p></ack><fn-group><fn><p>This work is published under the standard license to publish agreement. After 12 months the
work will become freely available and the license terms will switch to a Creative Commons
Attribution-NonCommercial-Share Alike 3.0 Unported License.</p></fn></fn-group><notes><p>The authors declare no conflict of interest.</p></notes><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrams</surname><given-names>TJ</given-names></name><name><surname>Lee</surname><given-names>LB</given-names></name><name><surname>Murray</surname><given-names>LJ</given-names></name><name><surname>Pryer</surname><given-names>NK</given-names></name><name><surname>Cherrington</surname><given-names>JM</given-names></name></person-group><year>2003a</year><article-title>SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical
models of human small cell lung cancer</article-title><source>Mol Cancer Ther</source><volume>2</volume><fpage>471</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">12748309</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrams</surname><given-names>TJ</given-names></name><name><surname>Murray</surname><given-names>LJ</given-names></name><name><surname>Pesenti</surname><given-names>E</given-names></name><name><surname>Holway</surname><given-names>VW</given-names></name><name><surname>Colombo</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>LB</given-names></name><name><surname>Cherrington</surname><given-names>JM</given-names></name><name><surname>Pryer</surname><given-names>NK</given-names></name></person-group><year>2003b</year><article-title>Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent
and in combination with &#x02018;standard of care' therapeutic agents for the
treatment of breast cancer</article-title><source>Mol Cancer Ther</source><volume>2</volume><fpage>1011</fpage><lpage>1021</lpage><pub-id pub-id-type="pmid">14578466</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>YJ</given-names></name><name><surname>Kang</surname><given-names>WK</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Kim</surname><given-names>HC</given-names></name><name><surname>Jacques</surname><given-names>C</given-names></name><name><surname>Zuber</surname><given-names>E</given-names></name><name><surname>Daglish</surname><given-names>B</given-names></name><name><surname>Boudraa</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>WS</given-names></name><name><surname>Heo</surname><given-names>DS</given-names></name><name><surname>Kim</surname><given-names>NK</given-names></name></person-group><year>2002</year><article-title>Docetaxel 75&#x02009;mg/m(2) is active and well tolerated in patients with
metastatic or recurrent gastric cancer: a phase II trial</article-title><source>Jpn J Clin Oncol</source><volume>32</volume><fpage>248</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">12324575</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>YJ</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Kang</surname><given-names>WK</given-names></name><name><surname>Boku</surname><given-names>N</given-names></name><name><surname>Chung</surname><given-names>HC</given-names></name><name><surname>Chen</surname><given-names>JS</given-names></name><name><surname>Doi</surname><given-names>T</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Ng</surname><given-names>WT</given-names></name><name><surname>Tursi</surname><given-names>JM</given-names></name><name><surname>Lechuga</surname><given-names>MJ</given-names></name><name><surname>Lu</surname><given-names>DR</given-names></name><name><surname>Ruiz-Garcia</surname><given-names>A</given-names></name><name><surname>Sobrero</surname><given-names>A</given-names></name></person-group><year>2010</year><article-title>Phase II study of sunitinib as second-line treatment for advanced gastric
cancer</article-title><source>Invest New Drugs</source><volume>29</volume><supplement>(6</supplement><fpage>1449</fpage><lpage>1458</lpage><pub-id pub-id-type="pmid">20461441</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barone</surname><given-names>C</given-names></name><name><surname>Basso</surname><given-names>M</given-names></name><name><surname>Schinzari</surname><given-names>G</given-names></name><name><surname>Pozzo</surname><given-names>C</given-names></name><name><surname>Trigila</surname><given-names>N</given-names></name><name><surname>D'Argento</surname><given-names>E</given-names></name><name><surname>Quirino</surname><given-names>M</given-names></name><name><surname>Astone</surname><given-names>A</given-names></name><name><surname>Cassano</surname><given-names>A</given-names></name></person-group><year>2007</year><article-title>Docetaxel and oxaliplatin combination in second-line treatment of patients with
advanced gastric cancer</article-title><source>Gastric Cancer</source><volume>10</volume><fpage>104</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">17577620</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Britten</surname><given-names>CD</given-names></name><name><surname>Kabbinavar</surname><given-names>F</given-names></name><name><surname>Hecht</surname><given-names>JR</given-names></name><name><surname>Bello</surname><given-names>CL</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Baum</surname><given-names>C</given-names></name><name><surname>Slamon</surname><given-names>D</given-names></name></person-group><year>2008</year><article-title>A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks,
followed by a 1-week off period</article-title><source>Cancer Chemother Pharmacol</source><volume>61</volume><fpage>515</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">17505827</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Christensen JG</surname><given-names>HC</given-names></name><name><surname>Hollister</surname><given-names>BA</given-names></name></person-group><year>2008</year><article-title>Antitumor efficacy of sunitinib malate in concurrent and sequential combinations
with standard chemotherapeutic agents in non-small cell lung cancer (NSCLC) nonclinical
models</article-title><source>Proceedings of the 99th Annual Meeting of the American Association for Cancer
Research</source><publisher-name>Philadelphia: PA, USA</publisher-name></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jonge</surname><given-names>MJ</given-names></name><name><surname>Dumez</surname><given-names>H</given-names></name><name><surname>Kitzen</surname><given-names>JJ</given-names></name><name><surname>Beuselinck</surname><given-names>B</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><name><surname>Courtney</surname><given-names>R</given-names></name><name><surname>Battista</surname><given-names>A</given-names></name><name><surname>Brega</surname><given-names>N</given-names></name><name><surname>Schoffski</surname><given-names>P</given-names></name></person-group><year>2011</year><article-title>Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel
in patients with advanced solid tumours</article-title><source>Eur J Cancer</source><volume>47</volume><fpage>1328</fpage><lpage>1335</lpage><pub-id pub-id-type="pmid">21439816</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demetri</surname><given-names>GD</given-names></name><name><surname>van Oosterom</surname><given-names>AT</given-names></name><name><surname>Garrett</surname><given-names>CR</given-names></name><name><surname>Blackstein</surname><given-names>ME</given-names></name><name><surname>Shah</surname><given-names>MH</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><name><surname>McArthur</surname><given-names>G</given-names></name><name><surname>Judson</surname><given-names>IR</given-names></name><name><surname>Heinrich</surname><given-names>MC</given-names></name><name><surname>Morgan</surname><given-names>JA</given-names></name><name><surname>Desai</surname><given-names>J</given-names></name><name><surname>Fletcher</surname><given-names>CD</given-names></name><name><surname>George</surname><given-names>S</given-names></name><name><surname>Bello</surname><given-names>CL</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Baum</surname><given-names>CM</given-names></name><name><surname>Casali</surname><given-names>PG</given-names></name></person-group><year>2006</year><article-title>Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal
tumour after failure of imatinib: a randomised controlled trial</article-title><source>Lancet</source><volume>368</volume><fpage>1329</fpage><lpage>1338</lpage><pub-id pub-id-type="pmid">17046465</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Donas</surname><given-names>J</given-names></name><name><surname>Esteban</surname><given-names>E</given-names></name><name><surname>Leandro-Garcia</surname><given-names>LJ</given-names></name><name><surname>Castellano</surname><given-names>DE</given-names></name><name><surname>del Alba</surname><given-names>AG</given-names></name><name><surname>Climent</surname><given-names>MA</given-names></name><name><surname>Arranz</surname><given-names>JA</given-names></name><name><surname>Gallardo</surname><given-names>E</given-names></name><name><surname>Puente</surname><given-names>J</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Mellado</surname><given-names>B</given-names></name><name><surname>Martinez</surname><given-names>E</given-names></name><name><surname>Moreno</surname><given-names>F</given-names></name><name><surname>Font</surname><given-names>A</given-names></name><name><surname>Robledo</surname><given-names>M</given-names></name><name><surname>Rodriguez-Antona</surname><given-names>C</given-names></name></person-group><year>2011</year><article-title>Single nucleotide polymorphism associations with response and toxic effects in
patients with advanced renal-cell carcinoma treated with first-line sunitinib: a
multicentre, observational, prospective study</article-title><source>Lancet Oncol</source><volume>12</volume><fpage>1143</fpage><lpage>1150</lpage><pub-id pub-id-type="pmid">22015057</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giuliani</surname><given-names>F</given-names></name><name><surname>Gebbia</surname><given-names>V</given-names></name><name><surname>De Vita</surname><given-names>F</given-names></name><name><surname>Maiello</surname><given-names>E</given-names></name><name><surname>Di Bisceglie</surname><given-names>M</given-names></name><name><surname>Catalano</surname><given-names>G</given-names></name><name><surname>Gebbia</surname><given-names>N</given-names></name><name><surname>Colucci</surname><given-names>G</given-names></name></person-group><year>2003</year><article-title>Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the
Gruppo Oncologico Italia Meridionale (G.O.I.M.)</article-title><source>Anticancer Res</source><volume>23</volume><fpage>4219</fpage><lpage>4222</lpage><pub-id pub-id-type="pmid">14666628</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Ekstrom</surname><given-names>K</given-names></name><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Graf</surname><given-names>W</given-names></name><name><surname>Sjoden</surname><given-names>PO</given-names></name><name><surname>Haglund</surname><given-names>U</given-names></name><name><surname>Svensson</surname><given-names>C</given-names></name><name><surname>Enander</surname><given-names>LK</given-names></name><name><surname>Linne</surname><given-names>T</given-names></name><name><surname>Sellstrom</surname><given-names>H</given-names></name><name><surname>Heuman</surname><given-names>R</given-names></name></person-group><year>1997</year><article-title>Randomized comparison between chemotherapy plus best supportive care with best
supportive care in advanced gastric cancer</article-title><source>Ann Oncol</source><volume>8</volume><fpage>163</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">9093725</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ilson</surname><given-names>DH</given-names></name></person-group><year>2007</year><article-title>Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit
the crime</article-title><source>J Clin Oncol</source><volume>25</volume><fpage>3188</fpage><lpage>3190</lpage><pub-id pub-id-type="pmid">17664464</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Center</surname><given-names>MM</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name></person-group><year>2011</year><article-title>Global cancer statistics</article-title><source>CA Cancer J Clin</source><volume>61</volume><fpage>69</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">21296855</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>KW</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Kong</surname><given-names>HJ</given-names></name><name><surname>Won</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>EC</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name></person-group><year>2011</year><article-title>Cancer statistics in Korea: incidence, mortality, survival, and prevalence in
2008</article-title><source>Cancer Res Treat</source><volume>43</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">21509157</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JA</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>JO</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Lim</surname><given-names>HY</given-names></name><name><surname>Kang</surname><given-names>WK</given-names></name></person-group><year>2011</year><article-title>Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in
metastatic gastric cancer</article-title><source>Cancer Chemother Pharmacol</source><volume>68</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">20878159</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JL</given-names></name><name><surname>Ryu</surname><given-names>MH</given-names></name><name><surname>Chang</surname><given-names>HM</given-names></name><name><surname>Kim</surname><given-names>TW</given-names></name><name><surname>Yook</surname><given-names>JH</given-names></name><name><surname>Oh</surname><given-names>ST</given-names></name><name><surname>Kim</surname><given-names>BS</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Chun</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name></person-group><year>2008</year><article-title>A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer
after failure of fluoropyrimidine and platinum combination chemotherapy</article-title><source>Cancer Chemother Pharmacol</source><volume>61</volume><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">17520252</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendel</surname><given-names>DB</given-names></name><name><surname>Laird</surname><given-names>AD</given-names></name><name><surname>Xin</surname><given-names>X</given-names></name><name><surname>Louie</surname><given-names>SG</given-names></name><name><surname>Christensen</surname><given-names>JG</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Schreck</surname><given-names>RE</given-names></name><name><surname>Abrams</surname><given-names>TJ</given-names></name><name><surname>Ngai</surname><given-names>TJ</given-names></name><name><surname>Lee</surname><given-names>LB</given-names></name><name><surname>Murray</surname><given-names>LJ</given-names></name><name><surname>Carver</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>E</given-names></name><name><surname>Moss</surname><given-names>KG</given-names></name><name><surname>Haznedar</surname><given-names>JO</given-names></name><name><surname>Sukbuntherng</surname><given-names>J</given-names></name><name><surname>Blake</surname><given-names>RA</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>T</given-names></name><name><surname>Shirazian</surname><given-names>S</given-names></name><name><surname>McMahon</surname><given-names>G</given-names></name><name><surname>Cherrington</surname><given-names>JM</given-names></name></person-group><year>2003</year><article-title><italic>In vivo</italic> antitumor activity of SU11248, a novel tyrosine kinase inhibitor
targeting vascular endothelial growth factor and platelet-derived growth factor receptors:
determination of a pharmacokinetic/pharmacodynamic relationship</article-title><source>Clin Cancer Res</source><volume>9</volume><fpage>327</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">12538485</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moehler</surname><given-names>M</given-names></name><name><surname>Mueller</surname><given-names>A</given-names></name><name><surname>Hartmann</surname><given-names>JT</given-names></name><name><surname>Ebert</surname><given-names>MP</given-names></name><name><surname>Al-Batran</surname><given-names>SE</given-names></name><name><surname>Reimer</surname><given-names>P</given-names></name><name><surname>Weihrauch</surname><given-names>M</given-names></name><name><surname>Lordick</surname><given-names>F</given-names></name><name><surname>Trarbach</surname><given-names>T</given-names></name><name><surname>Biesterfeld</surname><given-names>S</given-names></name><name><surname>Kabisch</surname><given-names>M</given-names></name><name><surname>Wachtlin</surname><given-names>D</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name></person-group><year>2011</year><article-title>An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for
patients with chemo-refractory advanced gastric cancer</article-title><source>Eur J Cancer</source><volume>47</volume><fpage>1511</fpage><lpage>1520</lpage><pub-id pub-id-type="pmid">21561763</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Tomczak</surname><given-names>P</given-names></name><name><surname>Michaelson</surname><given-names>MD</given-names></name><name><surname>Bukowski</surname><given-names>RM</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><name><surname>Pili</surname><given-names>R</given-names></name><name><surname>Bjarnason</surname><given-names>GA</given-names></name><name><surname>Garcia-del-Muro</surname><given-names>X</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Solska</surname><given-names>E</given-names></name><name><surname>Wilding</surname><given-names>G</given-names></name><name><surname>Thompson</surname><given-names>JA</given-names></name><name><surname>Kim</surname><given-names>ST</given-names></name><name><surname>Chen</surname><given-names>I</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Figlin</surname><given-names>RA</given-names></name></person-group><year>2009</year><article-title>Overall survival and updated results for sunitinib compared with interferon alfa in
patients with metastatic renal cell carcinoma</article-title><source>J Clin Oncol</source><volume>27</volume><fpage>3584</fpage><lpage>3590</lpage><pub-id pub-id-type="pmid">19487381</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>S</given-names></name><name><surname>Rebischung</surname><given-names>C</given-names></name><name><surname>Van Ongeval</surname><given-names>J</given-names></name><name><surname>Flesch</surname><given-names>M</given-names></name><name><surname>Bennamoun</surname><given-names>M</given-names></name><name><surname>Andre</surname><given-names>T</given-names></name><name><surname>Ychou</surname><given-names>M</given-names></name><name><surname>Gamelin</surname><given-names>E</given-names></name><name><surname>Carola</surname><given-names>E</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name></person-group><year>2006</year><article-title>Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and
first line treatment</article-title><source>Bull Cancer</source><volume>93</volume><fpage>E1</fpage><lpage>E6</lpage><pub-id pub-id-type="pmid">16455499</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishiyama</surname><given-names>M</given-names></name><name><surname>Wada</surname><given-names>S</given-names></name></person-group><year>2009</year><article-title>Docetaxel: its role in current and future treatments for advanced gastric
cancer</article-title><source>Gastric Cancer</source><volume>12</volume><fpage>132</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">19890692</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Farrell</surname><given-names>AM</given-names></name><name><surname>Abrams</surname><given-names>TJ</given-names></name><name><surname>Yuen</surname><given-names>HA</given-names></name><name><surname>Ngai</surname><given-names>TJ</given-names></name><name><surname>Louie</surname><given-names>SG</given-names></name><name><surname>Yee</surname><given-names>KW</given-names></name><name><surname>Wong</surname><given-names>LM</given-names></name><name><surname>Hong</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>LB</given-names></name><name><surname>Town</surname><given-names>A</given-names></name><name><surname>Smolich</surname><given-names>BD</given-names></name><name><surname>Manning</surname><given-names>WC</given-names></name><name><surname>Murray</surname><given-names>LJ</given-names></name><name><surname>Heinrich</surname><given-names>MC</given-names></name><name><surname>Cherrington</surname><given-names>JM</given-names></name></person-group><year>2003</year><article-title>SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity <italic>in
vitro</italic> and <italic>in vivo</italic></article-title><source>Blood</source><volume>101</volume><fpage>3597</fpage><lpage>3605</lpage><pub-id pub-id-type="pmid">12531805</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Lim</surname><given-names>DH</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Oh</surname><given-names>SY</given-names></name><name><surname>Kwon</surname><given-names>H</given-names></name><name><surname>Kang</surname><given-names>JH</given-names></name><name><surname>Hwang</surname><given-names>IG</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>JO</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Lim</surname><given-names>HY</given-names></name><name><surname>Kang</surname><given-names>WK</given-names></name></person-group><year>2011</year><article-title>A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC)
plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer
(AGC)</article-title><source>J Clin Oncol</source><volume>29</volume><supplement>Suppl</supplement>Abstract 4004</mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Kang</surname><given-names>WK</given-names></name><name><surname>Lee</surname><given-names>HR</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>KE</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>JO</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>WS</given-names></name><name><surname>Chung</surname><given-names>CW</given-names></name><name><surname>Im</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>MH</given-names></name><name><surname>Park</surname><given-names>CH</given-names></name><name><surname>Park</surname><given-names>K</given-names></name></person-group><year>2004</year><article-title>Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced
gastric cancer progressing on 5-fluorouracil-based regimen</article-title><source>Am J Clin Oncol</source><volume>27</volume><fpage>477</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">15596914</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pyrhonen</surname><given-names>S</given-names></name><name><surname>Kuitunen</surname><given-names>T</given-names></name><name><surname>Nyandoto</surname><given-names>P</given-names></name><name><surname>Kouri</surname><given-names>M</given-names></name></person-group><year>1995</year><article-title>Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus
supportive care with supportive care alone in patients with non-resectable gastric
cancer</article-title><source>Br J Cancer</source><volume>71</volume><fpage>587</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">7533517</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raymond</surname><given-names>E</given-names></name><name><surname>Dahan</surname><given-names>L</given-names></name><name><surname>Raoul</surname><given-names>JL</given-names></name><name><surname>Bang</surname><given-names>YJ</given-names></name><name><surname>Borbath</surname><given-names>I</given-names></name><name><surname>Lombard-Bohas</surname><given-names>C</given-names></name><name><surname>Valle</surname><given-names>J</given-names></name><name><surname>Metrakos</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Vinik</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>JS</given-names></name><name><surname>Horsch</surname><given-names>D</given-names></name><name><surname>Hammel</surname><given-names>P</given-names></name><name><surname>Wiedenmann</surname><given-names>B</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Patyna</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>DR</given-names></name><name><surname>Blanckmeister</surname><given-names>C</given-names></name><name><surname>Chao</surname><given-names>R</given-names></name><name><surname>Ruszniewski</surname><given-names>P</given-names></name></person-group><year>2011</year><article-title>Sunitinib malate for the treatment of pancreatic neuroendocrine tumors</article-title><source>N Engl J Med</source><volume>364</volume><fpage>501</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">21306237</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>F</given-names></name><name><surname>Sandler</surname><given-names>A</given-names></name><name><surname>Schiller</surname><given-names>JH</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Harper</surname><given-names>K</given-names></name><name><surname>Verkh</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Ilagan</surname><given-names>J</given-names></name><name><surname>Tye</surname><given-names>L</given-names></name><name><surname>Chao</surname><given-names>R</given-names></name><name><surname>Traynor</surname><given-names>AM</given-names></name></person-group><year>2010</year><article-title>Sunitinib in combination with docetaxel in patients with advanced solid tumors: a
phase I dose-escalation study</article-title><source>Cancer Chemother Pharmacol</source><volume>66</volume><fpage>669</fpage><lpage>680</lpage><pub-id pub-id-type="pmid">20043166</pub-id></mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>E</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Ioka</surname><given-names>A</given-names></name><name><surname>Nakahara</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name></person-group><year>2011</year><article-title>Trends of stomach cancer mortality in eastern Asia in 1950&#x02013;2004: Comparative
study of Japan, Hong Kong and Singapore using age, period and cohort analysis</article-title><source>Int J Cancer</source><volume>130</volume><supplement>4</supplement><fpage>930</fpage><lpage>936</lpage><pub-id pub-id-type="pmid">21425256</pub-id></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Haller</surname><given-names>D</given-names></name><name><surname>Ohtsu</surname><given-names>A</given-names></name></person-group><year>2002</year><article-title>The role of chemotherapy in the current treatment of gastric cancer</article-title><source>Gastric Cancer</source><volume>5</volume><supplement>Suppl 1</supplement><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">12772882</pub-id></mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Moiseyenko</surname><given-names>VM</given-names></name><name><surname>Tjulandin</surname><given-names>S</given-names></name><name><surname>Majlis</surname><given-names>A</given-names></name><name><surname>Constenla</surname><given-names>M</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Rodrigues</surname><given-names>A</given-names></name><name><surname>Fodor</surname><given-names>M</given-names></name><name><surname>Chao</surname><given-names>Y</given-names></name><name><surname>Voznyi</surname><given-names>E</given-names></name><name><surname>Risse</surname><given-names>ML</given-names></name><name><surname>Ajani</surname><given-names>JA</given-names></name></person-group><year>2006</year><article-title>Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin
and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325
Study Group</article-title><source>J Clin Oncol</source><volume>24</volume><fpage>4991</fpage><lpage>4997</lpage><pub-id pub-id-type="pmid">17075117</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Erp</surname><given-names>NP</given-names></name><name><surname>Eechoute</surname><given-names>K</given-names></name><name><surname>van der Veldt</surname><given-names>AA</given-names></name><name><surname>Haanen</surname><given-names>JB</given-names></name><name><surname>Reyners</surname><given-names>AK</given-names></name><name><surname>Mathijssen</surname><given-names>RH</given-names></name><name><surname>Boven</surname><given-names>E</given-names></name><name><surname>van der Straaten</surname><given-names>T</given-names></name><name><surname>Baak-Pablo</surname><given-names>RF</given-names></name><name><surname>Wessels</surname><given-names>JA</given-names></name><name><surname>Guchelaar</surname><given-names>HJ</given-names></name><name><surname>Gelderblom</surname><given-names>H</given-names></name></person-group><year>2009</year><article-title>Pharmacogenetic pathway analysis for determination of sunitinib-induced
toxicity</article-title><source>J Clin Oncol</source><volume>27</volume><fpage>4406</fpage><lpage>4412</lpage><pub-id pub-id-type="pmid">19667267</pub-id></mixed-citation></ref><ref id="bib33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>AD</given-names></name><name><surname>Grothe</surname><given-names>W</given-names></name><name><surname>Haerting</surname><given-names>J</given-names></name><name><surname>Kleber</surname><given-names>G</given-names></name><name><surname>Grothey</surname><given-names>A</given-names></name><name><surname>Fleig</surname><given-names>WE</given-names></name></person-group><year>2006</year><article-title>Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based
on aggregate data</article-title><source>J Clin Oncol</source><volume>24</volume><fpage>2903</fpage><lpage>2909</lpage><pub-id pub-id-type="pmid">16782930</pub-id></mixed-citation></ref><ref id="bib34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Ying</surname><given-names>JE</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yong</surname><given-names>D</given-names></name><name><surname>Hang</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Zhong</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name></person-group><year>2008</year><article-title>Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of
fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer</article-title><source>Anticancer Drugs</source><volume>19</volume><fpage>1013</fpage><lpage>1018</lpage><pub-id pub-id-type="pmid">18827567</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>Dose-normalised <italic>C</italic><sub>ss,av</sub> of sunitinib and SU12662 at each cycle.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2012100f1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>Time to progression curve of the patients.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2012100f2"/></fig><fig id="fig3"><label>Figure 3</label><caption><p>A case of complete response of docetaxel/sunitinib combination. (<bold>A</bold>) Baseline
image. (<bold>B</bold>) After four cycles of treatment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2012100f3"/></fig><fig id="fig4"><label>Figure 4</label><caption><p>Overall survival curve of the patients.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2012100f4"/></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Patients' characteristics</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50">
<bold>DS arm (</bold>
<italic>
<bold>n</bold>
</italic>
<bold>=56)</bold>
</th><th align="center" valign="top" charoff="50">
<bold>D arm (</bold>
<italic>
<bold>n</bold>
</italic>
<bold>=49)</bold>
</th><th align="center" valign="top" charoff="50"><italic><bold>P</bold></italic>-<bold>value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Age, median (range)</td><td align="char" valign="top" char="(" charoff="50">54.0 (20&#x02013;72)</td><td align="char" valign="top" char="(" charoff="50">52 (36&#x02013;70)</td><td align="char" valign="top" char="." charoff="50">0.356</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Sex (</italic>N (&#x00025;))</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Male</td><td align="char" valign="top" char="(" charoff="50">40 (71.4)</td><td align="char" valign="top" char="(" charoff="50">33 (67.3)</td><td align="char" valign="top" char="." charoff="50">0.650</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female</td><td align="char" valign="top" char="(" charoff="50">16 (28.6)</td><td align="char" valign="top" char="(" charoff="50">16 (32.7)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>ECOG (</italic>N (&#x00025;))</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;0</td><td align="char" valign="top" char="(" charoff="50">2 (3.6)</td><td align="char" valign="top" char="(" charoff="50">3 (6.1)</td><td align="char" valign="top" char="." charoff="50">0.603</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="char" valign="top" char="(" charoff="50">28 (85.7)</td><td align="char" valign="top" char="(" charoff="50">43 (87.8)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="char" valign="top" char="(" charoff="50">6 (10.7)</td><td align="char" valign="top" char="(" charoff="50">3 (6.1)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50">
<italic>Laboratory findings (median, range)</italic>
</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;WBC</td><td align="char" valign="top" char="(" charoff="50">6135 (2910&#x02013;17&#x02009;270)</td><td align="char" valign="top" char="(" charoff="50">5900 (3110&#x02013;12&#x02009;170)</td><td align="char" valign="top" char="." charoff="50">0.352</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Haemoglobin</td><td align="char" valign="top" char="(" charoff="50">10.9 (8.0&#x02013;17.1)</td><td align="char" valign="top" char="(" charoff="50">11.1 (8.4&#x02013;15.5)</td><td align="char" valign="top" char="." charoff="50">0.529</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Platelet</td><td align="center" valign="top" charoff="50">201&#x02009;000 (75&#x02009;000&#x02013;495&#x02009;000)</td><td align="center" valign="top" charoff="50">187&#x02009;000 (89000&#x02013;497&#x02009;000)</td><td align="char" valign="top" char="." charoff="50">0.094</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;ANC</td><td align="char" valign="top" char="(" charoff="50">3470 (1080&#x02013;13&#x02009;700)</td><td align="char" valign="top" char="(" charoff="50">3500 (1390&#x02013;9630)</td><td align="char" valign="top" char="." charoff="50">0.571</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Calcium</td><td align="char" valign="top" char="(" charoff="50">9.0 (7.1&#x02013;11.1)</td><td align="char" valign="top" char="(" charoff="50">9.0 (7.7&#x02013;10.5)</td><td align="char" valign="top" char="." charoff="50">0.138</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Creatinine</td><td align="char" valign="top" char="(" charoff="50">0.8 (0.4&#x02013;3.3)</td><td align="char" valign="top" char="(" charoff="50">0.8 (0.6&#x02013;6.4)</td><td align="char" valign="top" char="." charoff="50">0.312</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Total protein</td><td align="char" valign="top" char="(" charoff="50">6.5 (3.9&#x02013;7.8)</td><td align="char" valign="top" char="(" charoff="50">6.6 (4.6&#x02013;8.0)</td><td align="char" valign="top" char="." charoff="50">0.108</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Albumin</td><td align="char" valign="top" char="(" charoff="50">4.0 (1.9&#x02013;4.8)</td><td align="char" valign="top" char="(" charoff="50">4.1 (2.4&#x02013;4.9)</td><td align="char" valign="top" char="." charoff="50">0.484</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;ALP</td><td align="char" valign="top" char="(" charoff="50">80 (43&#x02013;975)</td><td align="char" valign="top" char="(" charoff="50">93 (45&#x02013;1418)</td><td align="char" valign="top" char="." charoff="50">0.029</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;AST</td><td align="char" valign="top" char="(" charoff="50">19 (11&#x02013;66)</td><td align="char" valign="top" char="(" charoff="50">24 (10&#x02013;58)</td><td align="char" valign="top" char="." charoff="50">0.980</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;ALT</td><td align="char" valign="top" char="(" charoff="50">14 (5&#x02013;38)</td><td align="char" valign="top" char="(" charoff="50">15 (5&#x02013;49)</td><td align="char" valign="top" char="." charoff="50">0.804</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Total bilirubin</td><td align="char" valign="top" char="(" charoff="50">0.5 (0.2&#x02013;2.3)</td><td align="char" valign="top" char="(" charoff="50">0.5 (0.2&#x02013;1.6)</td><td align="char" valign="top" char="." charoff="50">0.063</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Site of metastases (</italic>N, (&#x00025;))</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Liver</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.081</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Yes</td><td align="char" valign="top" char="(" charoff="50">24 (42.9)</td><td align="char" valign="top" char="(" charoff="50">13 (26.5)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;No</td><td align="char" valign="top" char="(" charoff="50">32 (57.1)</td><td align="char" valign="top" char="(" charoff="50">36 (73.5)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50">&#x02003;Lung</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Yes</td><td align="char" valign="top" char="(" charoff="50">5 (8.9)</td><td align="char" valign="top" char="(" charoff="50">8 (16.3)</td><td align="char" valign="top" char="." charoff="50">0.251</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;No</td><td align="char" valign="top" char="(" charoff="50">51 (91.1)</td><td align="char" valign="top" char="(" charoff="50">41 (83.7)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Abdominal lymph nodes</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.530</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Yes</td><td align="char" valign="top" char="(" charoff="50">32 (57.1)</td><td align="char" valign="top" char="(" charoff="50">25 (51.0)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;No</td><td align="char" valign="top" char="(" charoff="50">24 (42.9)</td><td align="char" valign="top" char="(" charoff="50">24 (49.0)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50">&#x02003;Neck lymph nodes</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Yes</td><td align="char" valign="top" char="(" charoff="50">2 (3.6)</td><td align="char" valign="top" char="(" charoff="50">2 (4.1)</td><td align="char" valign="top" char="." charoff="50">0.892</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;No</td><td align="char" valign="top" char="(" charoff="50">54 (96.4)</td><td align="char" valign="top" char="(" charoff="50">47 (95.9)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Peritoneal seeding</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.124</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Yes</td><td align="char" valign="top" char="(" charoff="50">17 (30.4)</td><td align="char" valign="top" char="(" charoff="50">22 (44.9)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;No</td><td align="char" valign="top" char="(" charoff="50">39 (69.6)</td><td align="char" valign="top" char="(" charoff="50">27 (55.1)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50">&#x02003;Bone</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Yes</td><td align="char" valign="top" char="(" charoff="50">3 (5.4)</td><td align="char" valign="top" char="(" charoff="50">4 (8.2)</td><td align="char" valign="top" char="." charoff="50">0.565</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;No</td><td align="char" valign="top" char="(" charoff="50">53 (94.6)</td><td align="char" valign="top" char="(" charoff="50">45 (91.8)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Number of metastatic sites (</italic>N (&#x00025;))</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;0</td><td align="char" valign="top" char="(" charoff="50">9 (16.1)</td><td align="char" valign="top" char="(" charoff="50">2 (4.1)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="char" valign="top" char="(" charoff="50">23 (41.1)</td><td align="char" valign="top" char="(" charoff="50">26 (53.1)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="char" valign="top" char="(" charoff="50">18 (32.1)</td><td align="char" valign="top" char="(" charoff="50">15 (30.6)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;3</td><td align="char" valign="top" char="(" charoff="50">6 (10.7)</td><td align="char" valign="top" char="(" charoff="50">6 (12.2)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Prior chemotherapy (</italic>N (&#x00025;))</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Capecitabine&#x0002b;cisplatin</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">74 (70.5&#x00025;)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;TS-1&#x0002b;cisplatin</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">18 (17.1&#x00025;)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Epirubicin&#x0002b;capecitabine&#x0002b;cisplatin</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">6 (5.7&#x00025;)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;FOLFOX</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">5 (4.8&#x00025;)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;TS-1&#x0002b;oxaliplatin</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">2 (1.9&#x00025;)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: ALP=alkaline phosphatase; ALT=alanine
aminotransferase; ANC=absolute neutrophil count; AST=aspartate
aminotransferase; D=docetaxel monotherapy;
DS=docetaxel&#x0002b;sunitinib; ECOG=Eastern Cooperative Oncology Group;
FOLFOX=oxaliplatin, 5-fluorouracil, leucovorin; WBC=white blood
corpuscles.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>Sunitinib and SU12662 pharmacokinetic variables at each cycle</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" char="&#x000b1;" charoff="50">
<bold>Cycle 2</bold>
</th><th align="center" valign="top" char="&#x000b1;" charoff="50">
<bold>Cycle 4</bold>
</th><th align="center" valign="top" char="&#x000b1;" charoff="50">
<bold>Cycle 6</bold>
</th><th align="center" valign="top" charoff="50">
<italic>
<bold>P</bold>
</italic>
<bold>-value</bold>
<xref ref-type="fn" rid="t2-fn2">
a
</xref>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Dose-normalised sunitinib <italic>C</italic><sub>ss,av</sub></td><td align="char" valign="top" char="&#x000b1;" charoff="50">31.2&#x000b1;6.33</td><td align="char" valign="top" char="&#x000b1;" charoff="50">33.1&#x000b1;9.63</td><td align="char" valign="top" char="&#x000b1;" charoff="50">32.5&#x000b1;10.33</td><td align="center" valign="top" charoff="50">0.8514</td></tr><tr><td align="left" valign="top" charoff="50">Dose-normalised SU12662 <italic>C</italic><sub>ss,av</sub></td><td align="char" valign="top" char="&#x000b1;" charoff="50">6.97&#x000b1;2.00</td><td align="char" valign="top" char="&#x000b1;" charoff="50">7.85&#x000b1;3.06</td><td align="char" valign="top" char="&#x000b1;" charoff="50">8.24&#x000b1;4.54</td><td align="center" valign="top" charoff="50">0.6157</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>Abbreviations: ANOVA=analysis of variance;
<italic>C</italic><sub>ss,av</sub>=average steady-state plasma concentrations.</p></fn><fn id="t2-fn2"><label>
a
</label><p>Repeated-measures ANOVA. Concentration values are shown as mean&#x000b1;s.d.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3"><label>Table 3</label><caption><title>Tumour response according to the treatment group</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" char="(" charoff="50">
<bold>DS arm (</bold>
<italic>
<bold>n</bold>
</italic>
<bold>=56)</bold>
</th><th align="center" valign="top" char="(" charoff="50">
<bold>D arm (</bold>
<italic>
<bold>n</bold>
</italic>
<bold>=49)</bold>
</th><th align="center" valign="top" char="(" charoff="50">
<bold>Total (</bold>
<italic>
<bold>n</bold>
</italic>
<bold>=105)</bold>
</th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Best response (</italic>N, &#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Complete response</td><td align="char" valign="top" char="(" charoff="50">1 (1.8)</td><td align="char" valign="top" char="(" charoff="50">0 (0.0)</td><td align="char" valign="top" char="(" charoff="50">1 (1.0)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Partial response</td><td align="char" valign="top" char="(" charoff="50">22 (39.3)</td><td align="char" valign="top" char="(" charoff="50">7 (14.3)</td><td align="char" valign="top" char="(" charoff="50">29 (27.6)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Stable disease</td><td align="char" valign="top" char="(" charoff="50">19 (33.9)</td><td align="char" valign="top" char="(" charoff="50">18 (36.7)</td><td align="char" valign="top" char="(" charoff="50">37 (35.2)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Progressive disease</td><td align="char" valign="top" char="(" charoff="50">14 (25.0)</td><td align="char" valign="top" char="(" charoff="50">24 (49.0)</td><td align="char" valign="top" char="(" charoff="50">38 (36.2)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Overall response rate (&#x00025;)</td><td align="center" valign="top" char="(" charoff="50">23/56 (41.1)</td><td align="center" valign="top" char="(" charoff="50">7/49 (14.3)</td><td align="center" valign="top" char="(" charoff="50"><italic>P</italic>=0.002</td></tr><tr><td align="left" valign="top" charoff="50">Disease control rate (&#x00025;)</td><td align="center" valign="top" char="(" charoff="50">42/56 (75.0)</td><td align="center" valign="top" char="(" charoff="50">25/49 (51.0)</td><td align="center" valign="top" char="(" charoff="50"><italic>P</italic>=0.011</td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><p>Abbreviations: D=docetaxel monotherapy;
DS=docetaxel&#x0002b;sunitinib.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl4"><label>Table 4</label><caption><title>Adverse events (<italic>N</italic>, &#x00025;)</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="2" align="center" valign="top" charoff="50">
<bold>DS arm</bold>
<hr/></th><th colspan="2" align="center" valign="top" charoff="50">
<bold>D arm</bold>
<hr/></th><th align="center" valign="top" charoff="50">&#x000a0;</th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50">
<bold>Grade 1&#x02013;2</bold>
</th><th align="center" valign="top" charoff="50">
<bold>Grade 3&#x02013;4</bold>
</th><th align="center" valign="top" charoff="50">
<bold>Grade 1&#x02013;2</bold>
</th><th align="center" valign="top" charoff="50">
<bold>Grade 3&#x02013;4</bold>
</th><th align="center" valign="top" charoff="50">
<italic>
<bold>P</bold>
</italic>
<bold>-value</bold>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Anaemia</td><td align="char" valign="top" char="(" charoff="50">45 (80.4)</td><td align="char" valign="top" char="(" charoff="50">6 (10.7)</td><td align="char" valign="top" char="(" charoff="50">41 (83.7)</td><td align="char" valign="top" char="(" charoff="50">5 (10.2)</td><td align="char" valign="top" char="." charoff="50">0.856</td></tr><tr><td align="left" valign="top" charoff="50">Leukopenia</td><td align="char" valign="top" char="(" charoff="50">13 (23.2)</td><td align="char" valign="top" char="(" charoff="50">12 (21.4)</td><td align="char" valign="top" char="(" charoff="50">5 (10.2)</td><td align="char" valign="top" char="(" charoff="50">7 (14.3)</td><td align="char" valign="top" char="." charoff="50">0.084</td></tr><tr><td align="left" valign="top" charoff="50">Neutropenia</td><td align="char" valign="top" char="(" charoff="50">8 (14.3)</td><td align="char" valign="top" char="(" charoff="50">18 (32.1)</td><td align="char" valign="top" char="(" charoff="50">4 (8.2)</td><td align="char" valign="top" char="(" charoff="50">10 (20.4)</td><td align="char" valign="top" char="." charoff="50">0.169</td></tr><tr><td align="left" valign="top" charoff="50">Thrombocytopenia</td><td align="char" valign="top" char="(" charoff="50">26 (46.4)</td><td align="char" valign="top" char="(" charoff="50">2 (3.6)</td><td align="char" valign="top" char="(" charoff="50">13 (26.5)</td><td align="char" valign="top" char="(" charoff="50">2 (4.1)</td><td align="char" valign="top" char="." charoff="50">0.107</td></tr><tr><td align="left" valign="top" charoff="50">Febrile neutropenia</td><td align="center" valign="top" charoff="50">N/A</td><td align="char" valign="top" char="(" charoff="50">15 (26.8)</td><td align="center" valign="top" charoff="50">N/A</td><td align="char" valign="top" char="(" charoff="50">8 (16.3)</td><td align="char" valign="top" char="." charoff="50">0.196</td></tr><tr><td align="left" valign="top" charoff="50">Nausea</td><td align="char" valign="top" char="(" charoff="50">19 (33.9)</td><td align="center" valign="top" charoff="50">none</td><td align="char" valign="top" char="(" charoff="50">13 (26.5)</td><td align="center" valign="top" charoff="50">none</td><td align="char" valign="top" char="." charoff="50">0.411</td></tr><tr><td align="left" valign="top" charoff="50">Vomiting</td><td align="char" valign="top" char="(" charoff="50">9 (16.1)</td><td align="center" valign="top" charoff="50">none</td><td align="char" valign="top" char="(" charoff="50">6 (12.2)</td><td align="center" valign="top" charoff="50">none</td><td align="char" valign="top" char="." charoff="50">0.576</td></tr><tr><td align="left" valign="top" charoff="50">Stomatitis</td><td align="char" valign="top" char="(" charoff="50">29 (51.8)</td><td align="center" valign="top" charoff="50">none</td><td align="char" valign="top" char="(" charoff="50">7 (14.3)</td><td align="center" valign="top" charoff="50">none</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" charoff="50">Diarrhoea</td><td align="char" valign="top" char="(" charoff="50">14 (25.0)</td><td align="char" valign="top" char="(" charoff="50">6 (10.7)</td><td align="char" valign="top" char="(" charoff="50">6 (12.2)</td><td align="char" valign="top" char="(" charoff="50">1 (2.0)</td><td align="char" valign="top" char="." charoff="50">0.033</td></tr><tr><td align="left" valign="top" charoff="50">Hand&#x02013;foot syndrome</td><td align="char" valign="top" char="(" charoff="50">27 (48.2)</td><td align="char" valign="top" char="(" charoff="50">3 (5.4)</td><td align="char" valign="top" char="(" charoff="50">10 (20.4)</td><td align="center" valign="top" charoff="50">none</td><td align="char" valign="top" char="." charoff="50">0.002</td></tr><tr><td align="left" valign="top" charoff="50">Neuropathy</td><td align="char" valign="top" char="(" charoff="50">37 (66.1)</td><td align="center" valign="top" charoff="50">none</td><td align="char" valign="top" char="(" charoff="50">28 (57.1)</td><td align="center" valign="top" charoff="50">none</td><td align="char" valign="top" char="." charoff="50">0.347</td></tr><tr><td align="left" valign="top" charoff="50">Myalgia</td><td align="char" valign="top" char="(" charoff="50">8 (14.3)</td><td align="center" valign="top" charoff="50">none</td><td align="char" valign="top" char="(" charoff="50">11 (22.4)</td><td align="char" valign="top" char="(" charoff="50">1 (2.0)</td><td align="char" valign="top" char="." charoff="50">0.295</td></tr></tbody></table><table-wrap-foot><fn id="t4-fn1"><p>Abbreviations: D=docetaxel monotherapy;
DS=docetaxel&#x0002b;sunitinib.</p></fn></table-wrap-foot></table-wrap></floats-group></article>